Application of High-Sensitivity Troponin in Suspected Myocardial Infarction.
Johannes T NeumannRaphael TwerenboldFrancisco OjedaNils A SörensenAndrew R ChapmanAnoop S V ShahAtul AnandJasper BoeddinghausThomas NestelbergerPatrick BadertscherArash MokhtariJohn W PickeringRichard W TroughtonJaimi GreensladeWilliam ParsonageMatthias Mueller-HennessenTommaso GoriTomas JernbergNiall MorrisChristoph LiebetrauChristian HammHugo A KatusThomas MünzelUlf LandmesserVeikko SalomaaLicia IacovielloMarco M FerrarioSimona GiampaoliFrank KeeBarbara ThorandAnnette PetersRossana BorchiniTorben JørgensenStefan SöderbergSusana SansHugh Tunstall-PedoeKari KuulasmaaThomas RennéKarl J LacknerAndrew WorsterRichard BodyUlf EkelundPeter A KavsakTill KellerBertil LindahlPhilipp WildEvangelos GiannitsisMartin ThanLouise A CullenNicholas L MillsChristian MuellerTanja ZellerDirk WestermannStefan BlankenbergPublished in: The New England journal of medicine (2019)
A risk-assessment tool, which we developed to integrate the high-sensitivity troponin I or troponin T concentration at emergency department presentation, its dynamic change during serial sampling, and the time between the obtaining of samples, was used to estimate the probability of myocardial infarction on emergency department presentation and 30-day outcomes. (Funded by the German Center for Cardiovascular Research [DZHK]; ClinicalTrials.gov numbers, NCT00470587, NCT02355457, NCT01852123, NCT01994577, and NCT03227159; and Australian New Zealand Clinical Trials Registry numbers, ACTRN12611001069943, ACTRN12610000766011, ACTRN12613000745741, and ACTRN12611000206921.).